Medication use for the treatment of diabetes in obese individuals.

about

Oxidative Stress and NLRP3-Inflammasome Activity as Significant Drivers of Diabetic Cardiovascular Complications: Therapeutic Implications.Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 Diabetes (SCORE-IT): study protocol for the development of a core outcome set

P2860

Q54260312-F7DDD261-F94E-4D30-B63A-31EDAB26226B Q57170511-C2FAFD5B-91C2-4CDB-B04C-099491C2345F

P2860

Medication use for the treatment of diabetes in obese individuals.

Item

http://www.wikidata.org/entity/Q39304674

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Medication use for the treatment of diabetes in obese individuals.

@en

Medication use for the treatment of diabetes in obese individuals.

@nl

type

Item

label

Medication use for the treatment of diabetes in obese individuals.

@en

Medication use for the treatment of diabetes in obese individuals.

@nl

prefLabel

Medication use for the treatment of diabetes in obese individuals.

@en

Medication use for the treatment of diabetes in obese individuals.

@nl

P1476

Medication use for the treatment of diabetes in obese individuals

@en

P2093

John P H Wilding

http://www.w3.org/2001/XMLSchema#string

P2860

A role for glucagon-like peptide-1 in the central regulation of feeding

Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.

Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol.

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial.

Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists.

Management of obesity.

Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.

P2888

s00125-017-4288-1

P304

265-272

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00125-017-4288-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

John Wilding

P577

2017-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28501906

http://www.w3.org/2001/XMLSchema#string

P921

Adipositas

P932

6448959

http://www.w3.org/2001/XMLSchema#string

Medication use for the treatment of diabetes in obese individuals.

about

P2860

P2860

Medication use for the treatment of diabetes in obese individuals.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932